A panelist discusses how integrating clinical trial data with real-world experience, patient-centered care, and shared decision-making enables retina specialists to individualize treatment plans, optimize adherence, and preserve vision in patients with geographic atrophy and neovascular AMD.
Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD
A panelist discusses how interpreting clinical trial data, monitoring disease progression, and maintaining transparent communication help retina specialists make informed decisions about when and how to treat geographic atrophy with emerging therapies.
Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.
Data suggests the candidate can reduce the number of injections and treatment burden for patients
In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.
A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient communication to build confidence and personalize treatment in evolving clinical settings.
Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.
The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.
The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.
ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.
EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.
During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.
At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.
